Table 1 Characteristics of population at baseline.
All participants | Remdesivir versus its control | HCQ versus its control | |||
|---|---|---|---|---|---|
(N = 108) | Remdesivir + SoC (n = 16) | SoC (n = 27) | HCQ + SoC (n = 40) | SoC (n = 47) | |
Demographics | |||||
Age, years | 58.0 (50.0, 65.3) | 58.0 (52.3, 62.0) | 61.0 (47.5, 68.5) | 55.0 (50.8, 74.0) | 61.0 (47.5, 69.5) |
Female, n (%) | 41 (38.0) | 6 (37.5) | 6 (22.2) | 17 (42.5) | 18 (38.3) |
Body Mass Index (kg/m2) | 27.6 (25.3, 30.7) | 27.3 (22.9, 32.6) | 27.2 (25.3, 28.3) | 27.8 (26.7, 31.8) | 27.2 (25.0, 28.9) |
Smoking history | |||||
Current, n (%) | 2 (1.9) | 1 (6.2) | 0 (0) | 1 (2.5) | 0 (0) |
Previous, n (%) | 40 (37.0) | 6 (37.5) | 12 (44.4) | 14 (35.0) | 18 (38.3) |
Never, n (%) | 62 (57.4) | 7 (43.7) | 14 (51.8) | 25 (62.5) | 27 (57.4) |
Comorbidities | |||||
Chronic pulmonary disease, n (%) | 5 (4.6) | 2 (12.5) | 0 (0) | 2 (5.0) | 1 (2.1) |
Hypertension, n (%) | 34 (31.5) | 5 (31.2) | 9 (33.3) | 11 (27.5) | 17 (36.2) |
Diabetes mellitus, n (%) | 17 (15.7) | 4 (25.0) | 1 (3.7) | 6 (15.0) | 7 (14.9) |
Obesity (BMI > 30 kg/m2), n (%) | 28 (25.9) | 6 (37.5) | 2 (7.4) | 14 (35.0) | 8 (17.0) |
Baseline characteristics | |||||
Duration of symptoms prior to baseline (days) | 8 (5.0, 10.0) | 8 (6.7, 9.5) | 8.0 (4.5, 9.0) | 8.0 (5.0, 10.0) | 8.0 (4.5, 9.5) |
P/F-ratio at admission (kPa) | 42.4 (32.5, 49.6) | 42.8 (30.4, 52.2) | 45.2 (36.9, 50.8) | 45.2 (31.6, 48.1) | 43.2 (35.8, 51.9) |
P/F-ratio < 40 kPa, n (%) | 40 (37.0) | 6 (37.5) | 10 (37.0) | 18 (45.0) | 14 (29.8) |
Respiration rate per minute | 21 (18, 24) | 21 (17.5, 24.0) | 20 (18.5, 24.0) | 20.5 (16.0, 24.0) | 21 (18.5, 24.0) |
Temperature (°C) | 37.3 (36.8, 38.0) | 37.1 (36.7, 37.6) | 37.3 (36.7, 37.8) | 37.5 (36.9, 38.2) | 37.2 (36.9, 37.9) |
Admission to ward, n (%) | 100 (92.6) | 14 (87.5) | 27 (100.0) | 35 (87.5) | 46 (97.9) |
Admission to ICU, n (%) | 8 (7.4) | 2 (12.5) | 0 (0) | 5 (12.5) | 1 (2.1) |
Biochemical presentation | |||||
Hemoglobin (g/dL) | 13.4 (12.2, 14.1) | 13.4 (12.2, 14.1) | 13.6 (12.5, 14.2) | 13.3 (12.2, 14.7) | 13.3 (12.4, 14.1) |
White blood cell count (× 109 per L) | 6.1 (4.6, 8.9) | 5.5 (30, 6.6) | 6.2 (4.8, 8.4) | 6.7 (4.5, 9.4) | 6.1 (4.9, 8.3) |
Lymphocytes (× 109 per L) | 1.1 (0.8, 1.4) | 1.0 (0.7, 1.53) | 1.0 (0.7, 1.9) | 1.0 (0.8, 1.3) | 1.1 (0.9, 1.4) |
Platelet count (× 109 per L) | 205 (163, 292) | 194 (171, 294) | 216 (162, 272) | 198 (155, 292) | 206 (165, 273) |
Creatinine (µmol/L) | 73.0 (57.0, 86.5) | 62.0 (53.0, 77.0) | 78.0 (59.0, 89.0) | 73.0 (58.0, 90.0) | 73.0 (56.5, 83.5) |
Ferritin (µg/L) | 627 (322, 1190) | 637 (386, 1420) | 627 (320, 1060) | 710 (276, 1390) | 532 (322, 990) |
Lactate dehydrogenase (U/L) | 275 (209, 357) | 280 (223, 321) | 214 (188, 357) | 276 (228, 367) | 255 (192, 353) |
CRP (mg/L) | 70.0 (34.8, 124.0) | 79.5 (24.8, 141.0) | 84.0 (31.5, 126) | 71.5 (46.8, 122.0) | 66.0 (30.5, 119.0) |
Viral load (oropharynx) | |||||
Viral load (log10 counts/1000 cells) | 1.73 (0.00, 0.48) | 1.85 (0.00, 4.51) | 1.36 (0.00, 4.83) | 1.88 (0.00, 4.27) | 1.53 (0.00, 4.83) |
Anti-SARS-CoV-2 antibodies | |||||
Seroconverted (RBD ≥ 5), n (%) | 42 (24.1) | 5 (31.2) | 11 (40.7) | 13 (32.5) | 20 (42.6) |
RBD (AU/mL) | 5.87 (2.26, 35.1) | 2.65 (1.79, 7.33) | 5.87 (2.41, 37.2) | 3.07 (2.38, 28.6) | 6.31 (2.21, 37.3) |
